Compare NODK & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NODK | FATE |
|---|---|---|
| Founded | 1946 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.2M | 260.0M |
| IPO Year | 2016 | 2013 |
| Metric | NODK | FATE |
|---|---|---|
| Price | $14.80 | $0.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.72 |
| AVG Volume (30 Days) | 11.6K | ★ 1.6M |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $285,050,000.00 | $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.72 |
| P/E Ratio | $17.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.37 | $0.95 |
| 52 Week High | $16.70 | $3.23 |
| Indicator | NODK | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 18.27 |
| Support Level | $14.80 | N/A |
| Resistance Level | $15.78 | $1.38 |
| Average True Range (ATR) | 0.49 | 0.15 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 33.48 | 2.18 |
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.